4.4 Editorial Material

The new dual gastric inhibitory peptide/glucagon-like peptide 1 agonist tirzepatide in type 2 diabetes: Is the future bright?

Journal

DIABETES-METABOLISM RESEARCH AND REVIEWS
Volume 37, Issue 8, Pages -

Publisher

WILEY
DOI: 10.1002/dmrr.3503

Keywords

antidiabetic therapy; gastric inhibitory peptide; glucagon-like peptide 1; tirzepatide; type 2 diabetes

Ask authors/readers for more resources

Tirzepatide is a dual GIP/GLP-1 receptor agonist with a long half-life, showing superiority in glycemic control and weight management in T2DM patients. While expected to enhance therapeutic options for T2DM, further data is needed for validation.
Tirzepatide is a dual gastric inhibitory peptide/glucagon-like peptide 1 (GIP/GLP-1) receptor agonist formulated as a synthetic linear peptide, based on the native GIP sequence. It has a prolonged half-life of 5 days, which enables once-weekly dosing. Studies have hitherto demonstrated its superiority in achieving optimal glycaemic control and body weight management, as compared with various agents used in the treatment of type 2 diabetes mellitus (T2DM), including GLP-1 receptor agonists. Thus, it is expected to enrich our therapeutic armamentarium in T2DM. However, further experience, notably longer follow-up data and information on cardiovascular effects, is still needed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available